Fax: (416) 586-8611
The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma
Article first published online: 11 OCT 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 10, pages 2682–2692, 15 May 2012
How to Cite
Riad, S., Biau, D., Holt, G. E., Werier, J., Turcotte, R. E., Ferguson, P. C., Griffin, A. M., Dickie, C. I., Chung, P. W., Catton, C. N., O'sullivan, B. and Wunder, J. S. (2012), The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer, 118: 2682–2692. doi: 10.1002/cncr.26543
- Issue published online: 3 MAY 2012
- Article first published online: 11 OCT 2011
- Manuscript Accepted: 2 AUG 2011
- Manuscript Revised: 1 AUG 2011
- Manuscript Received: 5 MAY 2011
- soft tissue sarcoma;
- limb salvage surgery;
- functional outcome;
Radiation-induced soft tissue sarcomas (RI-STS) are rare, and it is believed that they are associated with a poor prognosis.The authors of this report compared the clinical and functional outcomes of adults who had extremity RI-STS with the outcomes of adults with sporadic STS.
Forty-four patients who were diagnosed with RI-STS from 1989 to 2009 were identified from 4 prospectively collected databases. Patient demographics, surgical and adjuvant treatment parameters, and oncologic and functional outcomes were evaluated.
The median latent period from irradiation of the primary condition to RI-STS diagnosis was 16 years. The median radiotherapy dose used for the index condition was 45 gray. The median age at RI-STS diagnosis was 56 years. The most common primary diagnoses were breast cancer (36.4%) and lymphoma (34.1%). The most common RI-STS histologies were malignant fibrous histiocytoma (36.4%) and angiosarcoma (18.2%). Forty-two patients underwent surgery, 13 patients received adjuvant radiotherapy, and 8 patients received adjuvant chemotherapy. Systemic metastases occurred in 50% of treated patients (n = 21), and 26% (n = 11) developed local recurrence, the risk of which was lower among patients who received reirradiation (P = .043). The 5-year disease-free interval (DFI) and overall survival (OS) rates for patients with RI-STS who presented without metastasis were 36% and 44%, respectively. Patients who had International Union Against Cancer TNM stage III RI-STS had a significantly worse DFI compared with patients who had stage III sporadic STS (multivariate analysis, P = .051). Eighteen patients with RI-STS underwent functional assessment after surgery, and their results were comparable to those of patients with sporadic STS.
Despite aggressive surgical treatment, patients who have RI-STS remain at greater risk of both local and systemic recurrence compared with patients who have sporadic STS, but they can anticipate similar functional outcomes. Reirradiation can be relatively safe and effective if used properly. Cancer 2011. © 2011 American Cancer Society.